Analysts Set LivaNova PLC (LIVN) PT at $126.50
Shares of LivaNova PLC (NASDAQ:LIVN) have received an average rating of “Buy” from the eight brokerages that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $126.50.
LIVN has been the topic of a number of research reports. Stifel Nicolaus upped their price target on shares of LivaNova from $115.00 to $130.00 and gave the company a “buy” rating in a research note on Tuesday, July 24th. BidaskClub upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 26th. Needham & Company LLC reiterated a “buy” rating and issued a $135.00 price target (up previously from $128.00) on shares of LivaNova in a research note on Wednesday, August 1st. Zacks Investment Research lowered shares of LivaNova from a “buy” rating to a “hold” rating in a research note on Thursday, September 20th. Finally, Jefferies Financial Group upped their price target on shares of LivaNova to $150.00 and gave the company a “buy” rating in a research note on Tuesday, October 2nd.
Shares of LIVN stock opened at $120.16 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.21 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $6.11 billion, a PE ratio of 36.30, a PEG ratio of 3.77 and a beta of 0.94. LivaNova has a 52-week low of $76.14 and a 52-week high of $131.54.
In other LivaNova news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $123.49, for a total transaction of $123,490.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David S. Wise sold 1,500 shares of the stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,500 shares of company stock worth $1,002,355. 0.41% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the business. BlackRock Inc. lifted its holdings in shares of LivaNova by 7.3% during the 3rd quarter. BlackRock Inc. now owns 5,787,930 shares of the company’s stock worth $717,530,000 after acquiring an additional 394,915 shares during the period. RTW Investments LP lifted its stake in LivaNova by 207.9% in the 2nd quarter. RTW Investments LP now owns 431,000 shares of the company’s stock valued at $43,022,000 after purchasing an additional 291,000 shares during the last quarter. Wells Fargo & Company MN lifted its stake in LivaNova by 31.4% in the 2nd quarter. Wells Fargo & Company MN now owns 1,177,233 shares of the company’s stock valued at $117,511,000 after purchasing an additional 281,610 shares during the last quarter. Capital Research Global Investors bought a new position in LivaNova in the 3rd quarter valued at approximately $25,290,000. Finally, AQR Capital Management LLC lifted its stake in LivaNova by 106.7% in the 3rd quarter. AQR Capital Management LLC now owns 222,599 shares of the company’s stock valued at $27,595,000 after purchasing an additional 114,886 shares during the last quarter. Hedge funds and other institutional investors own 82.26% of the company’s stock.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.